Frontage Holdings Corporation (1521.HK) Stock

About Frontage Holdings Corporation

Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacokinetics (DMPK); safety and toxicology; early phase clinical services; and bioequivalence and related services, such as pharmacology, medical writing, and regulatory support. In addition, it offers pharmaceutical product development services, including intermediate and active pharmaceutical ingredient (API) synthesis, process and formulation development, and clinical trial material manufacturing. Further, the company provides laboratory testing services, such as bioanalysis, biomarkers, genomics, chemistry, manufacturing and controls (“CMC”) analytical testing, and central laboratory services. It operates in the United States, Canada, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. The company was founded in 2001 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation operates as a subsidiary of Hongkong Tigermed Consulting Co., ltd.

Frontage Holdings Corporation (1521.HK) stock trades at $1.26 with a market capitalization of $2.57B. The stock is valued at a price-to-earnings (P/E) ratio of 42.17, price-to-book of 0.94, price-to-sales of 9.99. Over the past 52 weeks the stock has ranged between $0.68 and $1.62, and currently trades 22.2% below its 52-week high.

On profitability, Frontage Holdings Corporation generates a return on equity (ROE) of 1.98%, an operating margin of 6.80%, a net profit margin of 2.65%.

Official website: www.frontagelab.com